Projects funded by the NCN
Dual CBR1-AKR1C3 inhibitors as a new approach to improve effectiveness and safety of anthracycline therapy.
2020/37/N/NZ7/01097
Keywords:
CBR1 AKR1C3 anthracyclines chemiotherapy cancer cardiotoxicity drug resistance
Descriptors:
- NZ7_014:
- NZ4_011:
- NZ5_007:
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Jagielloński, Collegium Medicum
woj. małopolskie
Principal investigator (from the host institution):
Number of co-investigators in the project: 3
Call: PRELUDIUM 19 - announced on 2020-03-16
Amount awarded: 139 980 PLN
Project start date (Y-m-d): 2021-01-19
Project end date (Y-m-d): 2023-09-18
Project duration:: 32 months (the same as in the proposal)
Project status: Project settled
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (1)
- In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline AntibioticsAuthors:Marek Jamrozik, Kamil Piska, Adam Bucki, Paulina Koczurkiewicz-Adamczyk, Michał Sapa, Benedykt Władyka, Elżbieta Pękala, Marcin KołaczkowskiAcademic press:Molecules (rok: 2023, tom: 28, strony: 3767), Wydawca: MDPIStatus:PublishedDOI:10.3390/molecules28093767 - link to the publication